The purpose of this project is to determine the reliability and validity of an instrument designed to assess functional ability of patients with Alzheimer's Disease (AD) enrolled in clinical treatment trials. At present functional scales measuring activities of daily living (ADLs) are often used as secondary but rarely as primary outcome measures either in trials of antidementia drugs or in trials of drugs for the treatment of ancillary symptoms such as agitation. Existing instruments are limited first because there is no consensus that they measure all of the major functional limitations found in AD patients and more importantly, that no existing instrument has been shown to be suitable for assessing functional change over a broad spectrum of dementia severity. Previously we have conducted reliability and longitudinal validity studies of the two most widely used instruments for assessing activities of daily living (ADLs) in AD patients, the Physical and Self-Maintenance Scale (PSMS) and Instrumental Activities of Daily Living Scale (IADLS) of Lawton and Brodie (1969). These studies have determined that many but not all of the items on these two scales have adequate reliability and longitudinal validity. We propose to modify some of the PSMS items to enhance reliability and to modify or replace several IADLS items so that they are less gender and location specific. Then we propose to assess the inter-rater, test-retest and alternate source reliability of each item; those with poor reliability will be eliminated or modified. Then a group of at least 50 AD patients with a wide range of baseline severity will be evaluated every six months for a minimum of 12 months. The ability of each item to measure longitudinal change for each level of dementia severity will be determined, and the reliability and sensitivity of the scale will be compared with other clinician rating scales used in clinical trials. The ultimate aim of the project is to produce an instrument for measuring activities of daily living (ADLs) in AD patients that can be used to evaluate the efficacy of drug treatments or other interventions.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
2P50AG005138-11
Application #
3745754
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
11
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10029
Zhu, Carolyn W; Grossman, Hillel; Neugroschl, Judith et al. (2018) A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer's disease: A pilot study. Alzheimers Dement (N Y) 4:609-616
Boban, Mirta; Babi? Leko, Mirjana; Miški?, Terezija et al. (2018) Human neuroblastoma SH-SY5Y cells treated with okadaic acid express phosphorylated high molecular weight tau-immunoreactive protein species. J Neurosci Methods :
Qian, Winnie; Fischer, Corinne E; Schweizer, Tom A et al. (2018) Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease. Curr Alzheimer Res 15:187-194
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021
Gallagher, Damien; Kiss, Alex; Lanctot, Krista et al. (2018) Depression and Risk of Alzheimer Dementia: A Longitudinal Analysis to Determine Predictors of Increased Risk among Older Adults with Depression. Am J Geriatr Psychiatry 26:819-827
Silverman, Jeremy M; Schmeidler, James (2018) Outcome age-based prediction of successful cognitive aging by total cholesterol. Alzheimers Dement 14:952-960
Haaksma, Miriam L; Calderón-Larrañaga, Amaia; Olde Rikkert, Marcel G M et al. (2018) Cognitive and functional progression in Alzheimer disease: A prediction model of latent classes. Int J Geriatr Psychiatry 33:1057-1064
Lin, Ming; Gong, Pinghua; Yang, Tao et al. (2018) Big Data Analytical Approaches to the NACC Dataset: Aiding Preclinical Trial Enrichment. Alzheimer Dis Assoc Disord 32:18-27
Ramsey, Christine M; Gnjidic, Danijela; Agogo, George O et al. (2018) Longitudinal patterns of potentially inappropriate medication use following incident dementia diagnosis. Alzheimers Dement (N Y) 4:1-10
Warren, Noel A; Voloudakis, Georgios; Yoon, Yonejung et al. (2018) The product of the ?-secretase processing of ephrinB2 regulates VE-cadherin complexes and angiogenesis. Cell Mol Life Sci 75:2813-2826

Showing the most recent 10 out of 555 publications